drugset / Trial / NCT07145112
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
Phase 1
Recruiting
20 enrolled
University of California, Davis
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe. The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lomustine | Small molecule | — | Oral |